Previous studies have shown widely varying estimates of the incidence of nonalcoholic fatty liver disease (NAFLD) in lean and nonobese individuals. In a new study, researchers sought to narrow that range...
The AGA has developed 8 best practice advice statements that address the screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.
Using data from the Fibrotic Liver Disease Consortium, authors of a new study evaluated ursodeoxycholic acid’s impact on patients with primary biliary cholangitis and whether the effects differ across...
Because clinicians often prescribe opioids for cirrhosis pain, authors of a new study assessed whether opioids affect patients’ risk of hepatic encephalopathy and, if so, what impact opioid use duration has...
Lindsay Sobotka, DO, from the Ohio State University Wexner Medical Center, presented her research at the ACG 2019 Annual Meeting about the risk of complications during pregnancy and outcomes among pregnant...
The authors of a new study presented at the ACG 2019 Annual Meeting examined the association between statin use and risk of HCC among more than 20,000 patients with HCC.
The FDA has expanded the approval of a new option for the treatment of adults and children aged 12 years or older or weighing at least 99 pounds with chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, or 6...
Authors of a new study evaluated the impact of tenofovir disoproxil fumarate on outcomes of more than 1000 individuals with chronic hepatitis B virus infection with cirrhosis.
The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
